{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:19:02Z","timestamp":1772165942029,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of transcatheter adrenal ablation as an alternative treatment for primary aldosteronism (PA) patients remains a subject of debate, with outcomes varying widely across existing studies. This meta-analysis aims to evaluate the results of adrenal ablation and estimate the effectiveness and safety of this therapeutic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search was conducted across PubMed, Embase, and Cochrane Library databases for studies published up to October 2022. Outcomes analyzed included the combined clinical success rate, biochemical success rate, and complication rate, which were assessed using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five studies, comprising 234 PA patients, were included in the analysis. The combined clinical success rate was 74% (95% CI: 69%-79%), and the biochemical success rate was 74% (95% CI: 53%-95%). Subgroup analysis revealed that the combined clinical success rate from Unilateral PA (72%, 95% CI: 46%-98%) was similar to the rate from Unilateral\u2009+\u2009Bilateral (73%, 95% CI: 52.0%-94.0%), while the clinical success rate of the PASO subgroup (78%, 95% CI: 66.0%-89.0%) was higher than the rate of other criteria (51%, 95% CI: 40.0%-63.0%). The combined complication rates were as follows: mild fever, 23% (95% CI: 12%-33%); back pain, 84% (95% CI: 77%-91%); and pleural effusion, 9% (95% CI: 0%-18%). All complications resolved within one week following the procedure. No late complications or ablation-related deaths were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Transcatheter adrenal ablation for PA patients is safe and demonstrates a relatively high clinical success rate. Presently, this approach is suitable for PA patients who are unwilling to undergo surgery or receive long-term mineralocorticoid receptor antagonist (MRA) treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review registration<\/jats:title>\n                    <jats:p>INPLASY, identifier 2022110076<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-023-01356-9","type":"journal-article","created":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T23:12:17Z","timestamp":1683501137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The outcomes of transcatheter adrenal ablation in patients with primary aldosteronism: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Shunfan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"issue":"5","key":"1356_CR1","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"RM Carey","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocr Metab. 2016;101(5):1889\u2013916.","journal-title":"J Clin Endocr Metab"},{"issue":"9","key":"1356_CR2","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/HJH.0000000000002441","volume":"38","author":"M Parasiliti-Caprino","year":"2020","unstructured":"Parasiliti-Caprino M, Lopez C, Prencipe N, Maccario M, Settanni F, Giraudo G, et al. Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J Hypertens. 2020;38(9):1841\u20138.","journal-title":"J Hypertens"},{"issue":"8","key":"1356_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1097\/HJH.0000000000001384","volume":"35","author":"E Rossi","year":"2017","unstructured":"Rossi E, Perazzoli F, Negro A, Magnani A. Diagnostic rate of primary aldosteronism in Emilia-Romagna, Northern Italy, during 16 years (2000\u20132015). J Hypertens. 2017;35(8):1691\u20137.","journal-title":"J Hypertens"},{"key":"1356_CR4","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1210\/jc.2013-2805","volume":"98","author":"P Mulatero","year":"2013","unstructured":"Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98:4826\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"1356_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","volume":"62","author":"GP Rossi","year":"2013","unstructured":"Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62:62\u20139.","journal-title":"Hypertension"},{"issue":"2","key":"1356_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","volume":"62","author":"S Savard","year":"2013","unstructured":"Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331\u20136.","journal-title":"Hypertension"},{"key":"1356_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00268-004-7496-z","volume":"29","author":"A Meyer","year":"2005","unstructured":"Meyer A, Brabant G, Behrend M. Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surgery. 2005;29:155\u20139.","journal-title":"World J Surgery"},{"issue":"2","key":"1356_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.21037\/gs.2018.10.06","volume":"8","author":"F Giurazza","year":"2019","unstructured":"Giurazza F, Corvino F, Silvestre M, Niola R, Cangiano G, Cavagli\u00e0 E, et al. Adrenal glands hemorrhages: embolization in acute setting. Gland Surg. 2019;8(2):115\u201322.","journal-title":"Gland Surg"},{"issue":"1","key":"1356_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2214\/AJR.12.9507","volume":"201","author":"MA Fowler","year":"2013","unstructured":"Fowler MA, Burda FJ, Kim KS. Adrenal artery embolization: anatomy, indications, and technical considerations. AJR Am J Roentgenol. 2013;201(1):190\u2013201.","journal-title":"AJR Am J Roentgenol"},{"issue":"Suppl 2","key":"1356_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/ccd.29554","volume":"97","author":"H Dong","year":"2021","unstructured":"Dong H, Zou Y, He J, Deng Y, Chen Y, Song L, et al. Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12-month results from a proof-of-principle trial. Catheter Cardio Inte. 2021;97(Suppl 2):976\u201381.","journal-title":"Catheter Cardio Inte"},{"issue":"9","key":"1356_CR11","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/jch.13960","volume":"22","author":"H Zhang","year":"2020","unstructured":"Zhang H, Li Q, Liu X, Zhao Z, He H, Sun F, et al. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof-of-principle trial. J Clin Hypertens. 2020;22(9):1618\u201326.","journal-title":"J Clin Hypertens"},{"key":"1356_CR12","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;\u00a0\u00a0https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"issue":"9","key":"1356_CR13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for nonrandomized studies (Minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136.","journal-title":"ANZ J Surg"},{"key":"1356_CR14","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; (6)327:557\u2013560.","DOI":"10.1136\/bmj.327.7414.557"},{"issue":"16","key":"1356_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","volume":"333","author":"J Lau","year":"2006","unstructured":"Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. 2006;333(16):597\u2013600.","journal-title":"BMJ"},{"issue":"2","key":"1356_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1148\/radiol.2272011798","volume":"227","author":"H Hokotate","year":"2003","unstructured":"Hokotate H, Inoue H, Baba Y, Tsuchimochi S, Nakajo M. Aldosteronomas: experience with superselective adrenal arterial embolization in 33 cases. Radiology. 2003;227(2):401\u20136.","journal-title":"Radiology"},{"key":"1356_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-01034-8","author":"F Sun","year":"2022","unstructured":"Sun F, Liu X, Zhang H, Zhou X, Zhao Z, He H, Yan Z, et al. Catheter-based adrenal ablation: an alternative therapy for patients with aldosterone-producing adenoma. Hypertens Res. 2022. https:\/\/doi.org\/10.1038\/s41440-022-01034-8.","journal-title":"Hypertens Res"},{"key":"1356_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpac105","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Liu Q, Wang X, Wan J, Liu S, Luo T, et al. Adrenal ablation versus mineralocorticoid receptor antagonism for the treatment of primary aldosteronism: A single-center prospective cohort study. AM J Hypertens. 2022. https:\/\/doi.org\/10.1093\/ajh\/hpac105.","journal-title":"AM J Hypertens"},{"issue":"9","key":"1356_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","volume":"5","author":"TA Williams","year":"2017","unstructured":"Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endo. 2017;5(9):689\u201399.","journal-title":"Lancet Diabetes Endo"},{"issue":"7","key":"1356_CR20","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1210\/jc.2008-2803","volume":"94","author":"N Sukor","year":"2009","unstructured":"Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab. 2009;94(7):2437\u201345.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1356_CR21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","volume":"71","author":"Y Ohno","year":"2018","unstructured":"Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, et al. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. Hypertension. 2018;71(3):530\u20137.","journal-title":"Hypertension"},{"issue":"5","key":"1356_CR22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/HJH.0000000000001251","volume":"35","author":"M Murata","year":"2017","unstructured":"Murata M, Kitamura T, Tamada D, Mukai K, Kurebayashi S, Yamamoto T, et al. Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. J Hypertens. 2017;35(5):1079\u201385.","journal-title":"J Hypertens"},{"key":"1356_CR23","doi-asserted-by":"crossref","unstructured":"Fu B, Zhang X, Wang GX, Bin Lang, Xin Ma, Hong-zhao Li, et al. Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol. 2011; 185(5):1578\u20131582.","DOI":"10.1016\/j.juro.2010.12.051"},{"issue":"6","key":"1356_CR24","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.euf.2020.06.023","volume":"7","author":"U Anceschi","year":"2021","unstructured":"Anceschi U, Tuderti G, Fiori C, Zappal\u00e0 O, Ferriero CM, Brassetti A, et al. Minimally invasive partial versus total adrenalectomy for the treatment of primary aldosteronism: results of a multicenter series according to the PASO Criteria. Eur Urol Focus. 2021;7(6):1418\u201323.","journal-title":"Eur Urol Focus"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-023-01356-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T23:12:21Z","timestamp":1683501141000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-023-01356-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1186\/s12902-023-01356-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2291493\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"19 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require ethics approval or participant consent given the nature of the work undertaken.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests..","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}